Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase I/II Study: Patient-individualized Peptide Vaccination Based on Whole Exome Sequencing With Adjuvant GM-CSF (Granulocyte Macrophage Colony-stimulating Factor) in Children and Young Adults With Primary/Relapsed Acute Lymphoblastic Leukemia

NCT03559413 is registered in ClinicalTrials.gov with University Children's Hospital Tuebingen as lead sponsor.

NCT NCT03559413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03559413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase I/II Study: Patient-individualized Peptide Vaccination Based on Whole Exome Sequencing With Adjuvant GM-CSF (Granulocyte Macrophage Colony-stimulating Factor) in Children and Young Adults With Primary/Relapsed Acute Lymphoblastic Leukemia
Lead sponsor
University Children's Hospital Tuebingen
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2016
Completion date
December 31, 2023
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

primary/relapsed acute lymphoblastic leukemia (all) of childhood, adolescents and young adults